147 related articles for article (PubMed ID: 31644966)
1. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
Nakamura R; Gendzekhadze K; Palmer J; Tsai NC; Mokhtari S; Forman SJ; Zaia JA; Senitzer D; Marcucci G; Stein A
Leuk Res; 2019 Dec; 87():106230. PubMed ID: 31644966
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.
Manjappa S; Bhamidipati PK; Stokerl-Goldstein KE; DiPersio JF; Uy GL; Westervelt P; Liu J; Schroeder MA; Vij R; Abboud CN; Fehniger TA; Cashen AF; Pusic I; Jacoby M; Meera SJ; Romee R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):46-52. PubMed ID: 24120526
[TBL] [Abstract][Full Text] [Related]
4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
5. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
7. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.
Busca A; Passera R; Pini M; Zallio F; Dellacasa C; Audisio E; Giaccone L; Maffini E; Costa C; Cavallo R; Bruno B
Am J Hematol; 2015 Jun; 90(6):E117-21. PubMed ID: 25752810
[TBL] [Abstract][Full Text] [Related]
8. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
9. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
[TBL] [Abstract][Full Text] [Related]
10. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
[TBL] [Abstract][Full Text] [Related]
11. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
12. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
[TBL] [Abstract][Full Text] [Related]
13. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J
Blood Adv; 2024 Feb; 8(3):581-590. PubMed ID: 38052043
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
15. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.
Stringaris K; Adams S; Uribe M; Eniafe R; Wu CO; Savani BN; Barrett AJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1257-64. PubMed ID: 20302958
[TBL] [Abstract][Full Text] [Related]
16. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
[TBL] [Abstract][Full Text] [Related]
17. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.
Gallez-Hawkins GM; Franck AE; Li X; Thao L; Oki A; Gendzekhadze K; Dagis A; Palmer J; Nakamura R; Forman SJ; Senitzer D; Zaia JA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1662-72. PubMed ID: 21596150
[TBL] [Abstract][Full Text] [Related]
18. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
[TBL] [Abstract][Full Text] [Related]
20. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
